Related Technology. Subject to the terms of this Agreement, Medical School hereby grants to Company and its Affiliates a non-exclusive, royalty-bearing license (with the right to sublicense) under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field.
Related Technology. University grants to Company a non-exclusive, royalty-bearing, perpetual license (with the right to sublicense) under its commercial rights in the Related Technology to make, have made, use, and sell Licensed Products and Licensed Services in the Field.
Related Technology. SKCC also hereby grants to Licensee a worldwide nonexclusive license under the Related Technology to manufacture, have manufactured, use, sell, import and export Licensed Products and to otherwise exploit the Related Technology. It is understood that this Section 3.1(b) shall not be deemed to limit Introgen's rights under Section 3.1(a) above.
Related Technology. During the Term of this Agreement, if: (i) USGN acquires rights, from a Third Party other than TIAX LLC, under any patented technology within the field of non-hazardous, non-toxic biological and/or chemical decontamination by or through the use of an aqueous, sprayable foam; and (ii) Kidde desires to sublicense such patented technology, the parties shall, in good faith, attempt to negotiate mutually acceptable terms and conditions applicable to the sublicensing of such technology. If the parties fail to negotiate a written agreement governing the use thereof, such technology shall not be included within the definition of Products under this Agreement and neither party shall be under any further obligation to, or have rights against, the other party with respect to such technology. Notwithstanding the foregoing, Kidde may acquire rights from a Third Party with respect to any biological and/or chemical decontamination products and/or technology that are not Covered by the USGN Patent Rights and such products and/or technology shall not be deemed to fall within the definition of Products under this Agreement and shall not be subject to any royalty obligations hereunder.
Related Technology. Roche acknowledges that in consideration of the collaboration established hereby and the enabling nature of the work previously done by Gilead, any influenza neuraminidase inhibitors as to which Roche or its Affiliates acquires rights prior to the fifth anniversary of the Effective Date, whether by reason of their own efforts or under contract from Third Parties, shall be included within the definition of Products under this Agreement, subject to the terms and conditions hereof. Similarly, Gilead acknowledges that its license to Roche hereunder covers all of the influenza neuraminidase inhibitors as to which it has rights or acquires rights prior to the fifth anniversary of the Effective Date.
Related Technology. Subject to the terms of this Agreement, Medical School hereby grants to Company and its Affiliates a non-exclusive, royalty-bearing license (with the right to sublicense) under its commercial rights in the Related Technology to develop, make, have made, use, sell, and have sold Licensed Products in the Field. UMass Agreement No. UMMC 03-33-06
Related Technology. Subject to the terms of this Agreement, University hereby grants to Company and its Affiliates a non-exclusive, worldwide, royalty-bearing license (with the right to sublicense) under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field.
Related Technology. The term "Related Technology" shall mean any research and development information, inventions, copyrightable materials, know-how, and all preclinical, clinical and other technical data in the possession of Xx. Xxxxxxx or ETI prior to the Effective Date, or during the Contract Research Period, in each case which relate directly to the Field or the Patent Rights and which ETI or Xx. Xxxxxxx has the right to provide to Pegas.
Related Technology. All technology, software, data, drawings, specifications, and other proprietary information or materials concerning the Product, including copies and duplicates, (“Technology”) provided by BRP to Supplier shall remain the property of BRP. Any Technology created (1) at the request of BRP, (2) in connection with Products sold only to BRP, or (3) based in whole or in part on information provided by BRP, shall be considered as ordered or commissioned by BRP as a contribution to a collective work, and be considered “work made-for-hire” and shall belong to BRP. To the extent such Technology may not be deemed “work made-for-hire,” Supplier and its employees, subcontractors and agents hereby assign, and BRP accepts, on a paid-up basis, all right, title and interest in and to all such Technology. Supplier shall not seek any registration, patent, copyright or titling of such Technology in its name or for its benefit. Supplier shall promptly execute and deliver such documents and take such action as BRP may reasonably request to protect or perfect BRP’s right, title and interest in the Technology. Supplier shall not supply to anyone other than BRP any Products designed in whole or in part by or exclusively for BRP.
Related Technology. Roche acknowledges that in consideration of the collaboration established hereby and the enabling nature of the work previously done by Gilead, any influenza neuraminidase inhibitors as to which Roche or its Affiliates acquires rights prior to the fifth anniversary of the Effective Date, whether by reason of their own efforts or under contract from Third Parties, shall be included within the definition of Products under this Agreement, subject to the terms and conditions hereof. Similarly, Gilead acknowledges that its license to Roche hereunder covers all of the influenza neuraminidase inhibitors as to which it has rights or acquires rights prior to the fifth anniversary of the Effective Date. [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
